TipRanks
Go Ultimate55% OFF

Parabilis Medicines, Inc. (PBLS) Financial Statements

Parabilis Medicines, Inc. Financial Overview

Parabilis Medicines, Inc.'s market cap is currently $3.50B. The company's EPS TTM is $-36.90; its P/E ratio is -0.77; Parabilis Medicines, Inc. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24
Income Statement
Total Revenue$ 0.00$ 0.00
Gross Profit$ 0.00$ 0.00
Operating Income$ -152.08M$ -126.13M
EBITDA$ -141.87M$ -114.33M
Net Income$ -145.89M$ -117.91M
Balance Sheet
Cash & Short-Term Investments$ 27.71M$ 87.98M
Total Assets$ 80.82M$ 149.25M
Total Debt$ 58.70M$ 66.20M
Net Debt$ 30.99M$ 18.91M
Total Liabilities$ 97.34M$ 92.81M
Stockholders' Equity$ -16.52M$ 56.44M
Cash Flow
Free Cash Flow$ -124.02M$ -104.49M
Operating Cash Flow$ -123.71M$ -103.61M
Investing Cash Flow$ 39.76M$ 30.24M
Financing Cash Flow$ 64.38M$ 78.08M

Currency in USD

Parabilis Medicines, Inc. Earnings and Revenue History

-180M-120M-60M00 %0.4 %0.8 %1.2 %EarningsProfit Margin20242025RevenueEarningsProfit Margin

Parabilis Medicines, Inc. Debt to Assets

060M120M180M50 %75 %100 %125 %LiabilitiesDebt to Assets20242025AssetsLiabilitiesDebt to Assets

Parabilis Medicines, Inc. Cash Flow

-150M-100M-50M050M100M20242025OperatingInvestingFinancing

Parabilis Medicines, Inc. Forecast EPS vs Actual EPS

-3-2-101Q2 26EPS EstimateBeatMiss